DDL24 concluded on Friday, December 13 with a half day of presentations and the final exhibition session. Bo Olsson of AstraZeneca kicked off the morning with a talk titled, “Validation of a General In Vitro Approach for Prediction of Total Lung Deposition in Healthy Adults.” After Olsson’s presentation, last year’s Pat Burnell award winner, Martin Rowland of the University of Bath, discussed “Measurement Methodologies for the Determination of Electrostatic Properties of Particles for Inhalation.”
The DDL24 exhibition came to an end after the morning coffee break. Malvern, one of the few exhibitors introducing any new products, had been showing a new accessory for its Morphologi G3-ID particle size and shape analyzer: a slide that fits into a cascade impactor to collect a sample from a particular stage.
Team Consulting announced new data related to its Occoris inhaler engine, which it introduced last year at RDD. According to Team, the new study shows that the Occoris engine achieves fine particle fractions of 70% or higher with high doses of carrier-free formulations and can be incorporated into breath-activated inhaler for only 20 US cents.
Avantis Pioneer was also showing a low-cost device, its Shake ‘N’ Dose indicator add-on. The indicator module fits on top of an MDI canister and indicates the amount of formulation left in the device with green, amber, and red lights. The patient can initiate a check of the amount by shaking the device; no actuation is necessary.